Cargando…

Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams

In order to develop original water soluble antagonists of X‐linked inhibitor of apoptosis protein (XIAP), a novel bicyclic scaffold was designed based on 8,5‐fused bicyclic lactam. During its preparation, a spontaneous rearrangement from 8,5‐ to 7,5‐fused bicyclic lactam was observed and confirmed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Zhaojun J., Shi, Yiming M., Xu, Ximing, Bellynck, Sébastien, Zhang, Kun, Du, Zhiyun Y., Xu, Xuetao, Maurel, François, Dong, Chang‐Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331714/
https://www.ncbi.nlm.nih.gov/pubmed/30652062
http://dx.doi.org/10.1002/open.201800260
_version_ 1783387188344389632
author Sheng, Zhaojun J.
Shi, Yiming M.
Xu, Ximing
Bellynck, Sébastien
Zhang, Kun
Du, Zhiyun Y.
Xu, Xuetao
Maurel, François
Dong, Chang‐Zhi
author_facet Sheng, Zhaojun J.
Shi, Yiming M.
Xu, Ximing
Bellynck, Sébastien
Zhang, Kun
Du, Zhiyun Y.
Xu, Xuetao
Maurel, François
Dong, Chang‐Zhi
author_sort Sheng, Zhaojun J.
collection PubMed
description In order to develop original water soluble antagonists of X‐linked inhibitor of apoptosis protein (XIAP), a novel bicyclic scaffold was designed based on 8,5‐fused bicyclic lactam. During its preparation, a spontaneous rearrangement from 8,5‐ to 7,5‐fused bicyclic lactam was observed and confirmed by MS and NMR analyses, in particular the HMBC spectra. DFT calculations were performed to understand the corresponding mechanism. It was finally prevented through changing the reaction order in the synthesis route and a Smac mimetic with this core structure, ZJ‐1 was successfully obtained. The structure of this new bicyclic scaffold was well confirmed by HRMS and NMR ((1)H, (13)C, NOESY) analyses. ZJ‐1 presented in addition a binding affinity to XIAP‐BIR3, nearly 6 times better than that of AVPI, similar to the reported SM‐128 in an in vitro fluorescence polarization (FP) assay. This preliminary result suggests that this new bicyclic scaffold could be very attractive in the development of novel anticancer agents targeting XIAP.
format Online
Article
Text
id pubmed-6331714
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63317142019-01-16 Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams Sheng, Zhaojun J. Shi, Yiming M. Xu, Ximing Bellynck, Sébastien Zhang, Kun Du, Zhiyun Y. Xu, Xuetao Maurel, François Dong, Chang‐Zhi ChemistryOpen Full Papers In order to develop original water soluble antagonists of X‐linked inhibitor of apoptosis protein (XIAP), a novel bicyclic scaffold was designed based on 8,5‐fused bicyclic lactam. During its preparation, a spontaneous rearrangement from 8,5‐ to 7,5‐fused bicyclic lactam was observed and confirmed by MS and NMR analyses, in particular the HMBC spectra. DFT calculations were performed to understand the corresponding mechanism. It was finally prevented through changing the reaction order in the synthesis route and a Smac mimetic with this core structure, ZJ‐1 was successfully obtained. The structure of this new bicyclic scaffold was well confirmed by HRMS and NMR ((1)H, (13)C, NOESY) analyses. ZJ‐1 presented in addition a binding affinity to XIAP‐BIR3, nearly 6 times better than that of AVPI, similar to the reported SM‐128 in an in vitro fluorescence polarization (FP) assay. This preliminary result suggests that this new bicyclic scaffold could be very attractive in the development of novel anticancer agents targeting XIAP. John Wiley and Sons Inc. 2019-01-15 /pmc/articles/PMC6331714/ /pubmed/30652062 http://dx.doi.org/10.1002/open.201800260 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Full Papers
Sheng, Zhaojun J.
Shi, Yiming M.
Xu, Ximing
Bellynck, Sébastien
Zhang, Kun
Du, Zhiyun Y.
Xu, Xuetao
Maurel, François
Dong, Chang‐Zhi
Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
title Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
title_full Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
title_fullStr Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
title_full_unstemmed Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
title_short Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams
title_sort development of xiap antagonists based on de novo 8,5‐fused bicyclic lactams
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331714/
https://www.ncbi.nlm.nih.gov/pubmed/30652062
http://dx.doi.org/10.1002/open.201800260
work_keys_str_mv AT shengzhaojunj developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT shiyimingm developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT xuximing developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT bellyncksebastien developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT zhangkun developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT duzhiyuny developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT xuxuetao developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT maurelfrancois developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams
AT dongchangzhi developmentofxiapantagonistsbasedondenovo85fusedbicycliclactams